Clinical Trial Update: Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for rituximab in multirelapsing minimal change disease or focal segmental glomerulosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Minimal Change Disease
• Nephrotic Syndrome

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Nephrotic Syndrome | Phase 3 | Status: COMPLETED